



Therapix Biosciences announces key appointments to the Company's management

Dr. Elran Haber was appointed CEO of the Company and Doron Ben Ami was appointed VP Strategy of the Company

Therapix, a company engaged in the development of drugs based on the active compounds in cannabis, announces today of key appointments to the Company's management. Dr. Elran Haber was appointed CEO of the Company. In the past eighteen months, Dr. Haber served as VP Business Strategy & Innovation of the Company. Dr. Elran Haber served over than 10 years collectively as Chairman and Board Director of several publicly traded, privately held companies (e.g. "Issta lines" Group (TASE), Amex Travel services – Israel) & various associations, and has been a member on variety of board committees. Dr. Haber held key roles at various life science start-ups & private investment firm, most recently as VP of Strategy & Business Development at ClearFarma industries Ltd.

Dr. Haber holds a PhD in Pharmaceutical Science from the Hebrew University of Jerusalem, and a MBA in Finance & Financial Engineering from the Hebrew University of Jerusalem.

In addition, the Company announced that it has appointed Mr. Doron Ben Ami as its VP Strategy. In such capacity, Mr. Ben Ami will be responsible for forming connections with strategic partners and for the business development of the Company's development plans.

Doron Ben Ami has over 20 years' experience in managing and leading companies in the pharmaceutical field. In his last role, Mr. Ben Ami served as Associate Vice President and Managing Director, Eastern Europe, Central Asia and Israel at Merck & Co. Inc. He additionally served as CEO of Merck's Israeli subsidiary.

Previously, Mr. Ben Ami held office as General Manager of the Israeli subsidiary of the pharmaceutical company Lundbeck. Mr. Ben Ami currently serves as senior consultant at the advisory firm Harel Consulting, which is located in the United States and specializes in connecting innovative pharma companies with international strategic partners. Doron Ben Ami holds a Master's degree in Health Systems Administration (MHA) from the Tel Aviv University.

Last week, Therapix announced the appointment of Prof. Raphael Mechoulam as member of the Company's scientific advisory board, further to the decision to focus the Company's business strategy on development cannabinoid based pharmaceuticals.

Prof. Raphael Mechoulam is a Professor Emeritus of the Department of Natural Products of the School of Pharmacy at the Faculty of Medicine of the Hebrew University of Jerusalem, and a member of the Israel Academy of Sciences and Humanities. He is a recipient of the Israel Prize in Exact Sciences - Chemistry, known for his work in identifying the main active compound in the cannabis plant, the THC, and is considered a world-renowned expert. Prof. Mechoulam began his work in this field at the beginning of the sixties and was the first person to synthesize THC.

About Therapix

Therapix Biosciences Ltd., is a biopharmaceutical company focused on identifying and investing in promising technologies in the biopharmaceutical field, while placing an emphasis on technologies that are based on a known biological mechanism which has passed the proof-of-concept phase, and which provide a solution for significant medical needs in the market and involve an investment of up to \$2 million for achieving a material milestone. The Company focuses on the creation and expansion of a portfolio of technologies and assets in the field of treatments based on cannabinoids (active compounds in the cannabis plant), and is currently examining the advancement of research and development programs of a cannabinoid-based medical product for treating Tourette's syndrome (under an orphan drug designation) as well as additional cognitive disorders.